Hemostemix (HEM) AI Stock Analysis

• Market Cap: C$18.16M
• Dividend Yield: N/A
• Average Volume (3M): 250.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.23
• Revenue Growth: N/A
• EPS Growth: 43.45%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 145,312,710
• 10 Day Avg. Volume: 491,515
• 30 Day Avg. Volume: 250,883
• PEG Ratio: 0.07
• Price to Book (P/B): -1.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -67.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

Hemostemix's stock is primarily hindered by its poor financial performance, characterized by no revenue and high leverage. The technical analysis points to positive momentum, but valuation concerns due to negative earnings are significant. The absence of earnings call data and impactful corporate events limits further insights.

Hemostemix Business Overview & Revenue Model

Company Description

Hemostemix Inc. (HEM) is a biotechnology company focused on developing and commercializing innovative therapies for diseases related to blood and circulatory systems. The company's core product, ACP-01, is a stem cell therapy designed to treat critical limb ischemia, a severe obstruction of the arteries that reduces blood flow to the extremities. Hemostemix is committed to advancing regenerative medicine by leveraging its proprietary technology platform to address unmet medical needs in cardiovascular and other related conditions.

How the Company Makes Money

Hemostemix makes money primarily through the development, licensing, and commercialization of its stem cell therapies. Its key revenue streams include potential licensing agreements with pharmaceutical companies, research grants, and partnerships for co-development of its therapies. Additionally, the company may generate income from milestone payments and royalties upon successful commercialization of its treatments. Hemostemix also explores opportunities for strategic collaborations to enhance its product pipeline and expand its market reach. However, as a biotechnology company in the pre-commercialization stage, it may not yet have significant revenue streams from product sales.

Hemostemix Financial Statement Overview

Summary

Hemostemix's financial health is precarious, with no revenue generation, significant losses, high leverage, and poor cash flow management. The company faces substantial financial distress, highlighting a need for strategic operational improvements and potential funding solutions.

Income Statement

Hemostemix has struggled with consistent revenue generation, as evidenced by zero revenue over the years. The company faces significant profitability challenges, with consistently negative net income and EBIT margins. There is no revenue growth, and high operating losses persist, indicating a need for strategic realignment to achieve financial sustainability.

Balance Sheet

The company's balance sheet highlights a concerning leverage situation with negative stockholder equity and a very high debt-to-equity ratio, indicating financial instability. The lack of equity and substantial liabilities present risks and limit financial flexibility. Total assets have decreased over time, exacerbating the leverage issue.

Cash Flow

Hemostemix faces significant cash flow challenges, with consistent negative operating and free cash flows, indicating reliance on external financing to maintain operations. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash generation relative to earnings. The company needs to improve its cash flow management to avoid liquidity issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-106.00	-223.00	-495.00	-1.10K	-2.45K	-1.69K
	EBIT
-1.10M	-2.33M	-4.58M	-6.67M	-7.47M	-4.70M
	EBITDA
-2.02M	-1.95M	-4.39M	-6.45M	-7.47M	-4.76M
	Net Income Common Stockholders
-2.99M	-2.50M	-5.24M	-6.29M	-7.77M	-4.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.47M	155.42K	135.75K	219.44K	257.95K	24.06K
	Total Assets
1.66M	313.76K	465.35K	563.05K	2.32M	104.28K
	Total Debt
0.00	4.32M	4.13M	1.48M	175.00K	2.06M
	Net Debt
-1.47M	4.17M	3.99M	1.26M	-82.95K	2.04M
	Total Liabilities
1.17M	7.68M	7.23M	5.85M	3.42M	4.15M
	Stockholders Equity
487.80K	-7.37M	-6.77M	-5.28M	-1.10M	-4.05M
Cash Flow		Free Cash Flow
-332.57K	-1.42M	-6.10M	-3.48M	-5.98M	-3.41M
	Operating Cash Flow
-332.57K	-1.42M	-6.10M	-3.48M	-5.98M	-3.40M
	Investing Cash Flow
0.00	0.00	0.00	171.12K	0.00	-6.14K
	Financing Cash Flow
18.31K	1.44M	6.02M	3.27M	6.21M	1.96M

Hemostemix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEM, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.10, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.58 is Neutral, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:HEM.

Hemostemix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
ZEN	43 Neutral	C$211.75M	―	-54.98%	―	92.38%	12.79%
VSBY	41 Neutral	$4.69M	―	260.66%	―	―	―
HEM	41 Neutral	C$18.16M	―	34.47%	―	―	43.45%
SVA	33 Underperform	C$55.84M	―	248.46%	―	―	32.71%

Hemostemix Corporate Events

Hemostemix Raises $2.67M to Boost Stem Cell Research

Hemostemix Inc. successfully concluded its private placement, raising a total of $2,675,981 to advance its stem cell therapeutics platform. The proceeds will be used for product development, sales initiation, and general operations, highlighting the company’s commitment to its innovative medical solutions.

Hemostemix Secures $1.8M in Private Placement

Hemostemix has successfully closed the first tranche of its private placement, raising approximately $1.8 million to boost its stem cell therapeutics platform and other operational needs. The funding will support initiatives like the initial sales and processing of angiogenic cell precursors (ACP). Additionally, Hemostemix granted stock options to its directors and officers, furthering its strategic business goals.